Protein Quality Control in Neurodegeneration

Protein Quality Control in Neurodegeneration

Protein homeostasis (proteostasis) is a fundamental cellular process that ensures the proper folding, assembly, trafficking, and degradation of proteins within cells. The maintenance of proteostasis is particularly critical in neurons, which are long-lived, post-mitotic cells that cannot dilute accumulated damaged proteins through cell division. Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, are characterized by the accumulation of misfolded protein aggregates, suggesting that failures in protein quality control (PQC) systems play a central role in neuronal dysfunction and death. This article provides a comprehensive overview of the molecular mechanisms underlying cellular PQC systems, their specific adaptations in neurons, and how their dysregulation contributes to neurodegeneration.

Introduction: The Proteostasis Network in the Nervous System

Protein Quality Control in Neurodegeneration

Protein homeostasis (proteostasis) is a fundamental cellular process that ensures the proper folding, assembly, trafficking, and degradation of proteins within cells. The maintenance of proteostasis is particularly critical in neurons, which are long-lived, post-mitotic cells that cannot dilute accumulated damaged proteins through cell division. Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, are characterized by the accumulation of misfolded protein aggregates, suggesting that failures in protein quality control (PQC) systems play a central role in neuronal dysfunction and death. This article provides a comprehensive overview of the molecular mechanisms underlying cellular PQC systems, their specific adaptations in neurons, and how their dysregulation contributes to neurodegeneration.

Introduction: The Proteostasis Network in the Nervous System

The proteostasis network comprises an intricate array of molecular machinery responsible for monitoring and maintaining protein folding homeostasis. This system includes molecular chaperones that assist in proper protein folding, degradation pathways that eliminate irreversibly damaged proteins, and quality control checkpoints that ensure only properly folded proteins reach their functional destinations [Hartl and Hayer-Hartl (2009)](https://pubmed.ncbi.nlm.nih.gov/19578124/)[@hartl2009]. The collective failure of these systems leads to proteotoxic stress, a hallmark of virtually all neurodegenerative disorders.

Neurons face unique challenges in maintaining proteostasis. Their extreme longevity, complex morphology with extensive dendritic and axonal compartments, and high metabolic demand make them particularly vulnerable to proteostatic disruptions [Soto and Estrada (2008)](https://pubmed.ncbi.nlm.nih.gov/18682243/)[@soto2008]. Furthermore, the brain's limited regenerative capacity means that neuronal loss is largely irreversible, emphasizing the importance of understanding PQC mechanisms in neuroprotection.

Pathway Diagram

Molecular Mechanisms of Protein Quality Control

The Ubiquitin-Proteasome System

The ubiquitin-proteasome system (UPS) represents the primary pathway for targeted protein degradation in eukaryotic cells. This system involves the covalent attachment of ubiquitin molecules to target proteins, marking them for degradation by the 26S proteasome [Ciechanover and Brundin (2003)](https://pubmed.ncbi.nlm.nih.gov/14502297/)[@ciechanover2003].

Ubiquitination Cascade: The ubiquitination process requires three key enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase). The diversity of E3 ligases—over 600 in humans—provides substrate specificity to the system [Deshaies and Joazeiro (2009)](https://pubmed.ncbi.nlm.nih.gov/19489737/)[@deshaies2009]. Polyubiquitin chains linked through lysine-48 (K48) typically target proteins for proteasomal degradation, while K63-linked chains serve non-degradative functions including signaling, endocytosis, and DNA repair.

26S Proteasome Structure and Function: The 26S proteasome consists of a 20S core particle (CP) flanked by one or two 19S regulatory particles (RP). The 20S CP is a barrel-shaped structure composed of four stacked heptameric rings (α₇β₇β₇α₇) that form a central chamber where proteolysis occurs [Groll et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10806026/)[@groll2000]. The 19S RP recognizes ubiquitinated substrates, removes ubiquitin chains, unfolds the substrate, and translocates it into the 20S CP for degradation. Ubiquitin molecules are recycled for subsequent rounds of ubiquitination.

Role in Neurodegeneration: Mutations in genes encoding PQC components directly cause or increase susceptibility to neurodegenerative diseases. For example, mutations in the E3 ligase parkin (PRKN) cause autosomal recessive Parkinson's disease [Kitada et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9837565/)[@kitada1998], while mutations in the deubiquitinating enzyme USP9X are linked to neurodegenerative conditions [Murtaza et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25823658/)[@murtaza2015]. The accumulation of ubiquitinated protein inclusions in sporadic neurodegenerative diseases suggests broader UPS impairment [Dickson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20431186/)[@dickson2010].

Autophagy-Lysosome Pathway

The autophagy-lysosome pathway (ALP) degrades large protein aggregates, damaged organelles, and intracellular pathogens through lysosomal hydrolysis. Three major forms of autophagy exist: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), each with distinct mechanisms and physiological roles [Mizushima and Komatsu (2011)](https://pubmed.ncbi.nlm.nih.gov/22021864/)[@mizushima2011].

Macroautophagy: This process involves the formation of double-membraned autophagosomes that engulf cytoplasmic cargo and fuse with lysosomes. The initiation of autophagosome formation requires the ULK1 complex and Beclin1-PI3KIII complex, while cargo recognition involves selective autophagy receptors such as p62/SQSTM1, which bind both ubiquitin chains on cargo and LC3 on the nascent autophagosome membrane [Johansen and Lamark (2011)](https://pubmed.ncbi.nlm.nih.gov/21779853/)[@johansen2011]. The fusion of autophagosomes with lysosomes requires SNARE proteins, VAMP8, and the HOPS complex [Yu et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29358643/)[@yu2018].

Chaperone-Mediated Autophagy: CMA uniquely targets individual soluble proteins for lysosomal degradation. Proteins containing a KFERQ motif are recognized by Hsc70 (heat shock cognate 70 kDa), which, together with co-chaperones, delivers them to the lysosomal receptor LAMP-2A [Cuervo and Dice (1996)](https://pubmed.ncbi.nlm.nih.gov/8656280/)[@cuervo1996]. Substrate unfolding and translocation through the LAMP-2A multimeric complex requires lysosomal Hsc70 activity. CMA is particularly important in neurons, where it degrades specific disease-related proteins including [alpha-synuclein](/proteins/alpha-synuclein) and the tau protein [Cuervo et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15149434/)[@cuervo2004].

Implications for Neurodegeneration: Dysregulation of autophagy is strongly implicated in neurodegenerative diseases. Beclin1 haploinsufficiency reduces autophagy and promotes neurodegeneration in mouse models [Pickford et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18682251/)[@pickford2008], while pharmacological enhancement of autophagy protects against protein aggregate toxicity [Sarkar et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17640570/)[@sarkar2007]. The accumulation of autophagic vacuoles in affected brain regions of Alzheimer's and Parkinson's disease patients indicates impaired autophagic flux [Nixon et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16257968/)[@nixon2005].

Molecular Chaperones

Molecular chaperones constitute a diverse family of proteins that facilitate proper protein folding, prevent aggregation, and assist in the refolding or degradation of misfolded proteins. They are classified based on their function and structure, with heat shock proteins (HSPs) representing the most extensively studied group [Hartl et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21689889/)[@hartl2011].

Hsp70 Family: Hsp70 proteins are central to the cellular chaperone network. They contain an N-terminal ATPase domain and a C-terminal substrate-binding domain. The ATPase domain regulates substrate binding affinity—ATP-bound Hsp70 has low substrate affinity, while ADP-bound Hsp70 has high affinity. Co-chaperones including Hsp40 (DnaJ) and nucleotide exchange factors (NEFs) regulate the Hsp70 cycle [Mayer and Bukau (2005)](https://pubmed.ncbi.nlm.nih.gov/15687258/)[@mayer2005]. In neurons, Hsp70 localizes to synapses and protects against age-related proteotoxic stress [Toth et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18337716/)[@toth2008].

Hsp90 and Hsp70 Co-chaperones: Hsp90 specializes in folding signaling proteins including kinases, steroid receptors, and transcription factors. Its function requires numerous co-chaperones that regulate the ATPase cycle and facilitate substrate loading [Taipale et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20562880/). The Hsp90-based chaperone system interfaces with the UPS through the co-chaperone Cdc37 and through ubiquilin proteins that deliver Hsp90 substrates for degradation [Stankiewicz et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20077431/).

Small Heat Shock Proteins: Small Hsp (sHsp) proteins form large oligomeric complexes that serve as first responders to proteotoxic stress. They prevent protein aggregation and can transfer substrates to the Hsp70/Hsp90 system for proper refolding or degradation [Haslbeck et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16030178/). Mutations in HspB1 (Hsp27) and HspB8 cause Charcot-Marie-Tooth disease, a peripheral neuropathy, highlighting the importance of chaperones in neuronal health [Evgrafov et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15527590/)[@evgrafov2004].

Endoplasmic Reticulum-Associated Degradation

The endoplasmic reticulum (ER) is the primary site for folding of secretory and membrane proteins. When protein folding fails, the unfolded protein response (UPR) is activated to restore ER homeostasis. If homeostasis cannot be achieved, ER-associated degradation (ERAD) targets misfolded proteins for retrotranslocation to the cytosol and subsequent ubiquitination and proteasomal degradation [Brodsky and Skach (2011)](https://pubmed.ncbi.nlm.nih.gov/21840891/)[@brodsky2011].

ERAD Components: The ERAD machinery includes lectins that recognize misfolded glycoproteins (EDEM, OS-9), a retrotranslocon channel (Sec61 or Derlin proteins), ubiquitin ligase complexes (Hrd1, Doa10), and the CDC48/p97 AAA-ATPase complex that extracts substrates from the ER membrane [Christianson et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22648169/). The importance of ERAD in neuronal function is demonstrated by the neurodegenerative disease hereditary spastic paraplegia, caused by mutations in the ERAD component atlastin-1 [Sanderson et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16272020/).

ER Stress and the UPR: Three ER transmembrane sensors—IRE1, PERK, and ATF6—detect misfolded protein accumulation and initiate the UPR. IRE1 splices XBP1 mRNA to produce a transcription factor that upregulates chaperones and ERAD components. PERK phosphorylate eIF2α to reduce translation load, while ATF6 is cleaved to produce a transcription activator [Walter and Ron (2011)](https://pubmed.ncbi.nlm.nih.gov/22082967/)[@walter2011]. Chronic ER stress, as occurs in many neurodegenerative diseases, leads to apoptotic signaling through CHOP and JNK pathways.

Protein Quality Control in Neurons

Neurons have evolved specialized adaptations of the general PQC machinery to address their unique challenges. The spatial organization of PQC components, particularly in synapses and axons, is crucial for neuronal function [Klein et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31794178/).

Axonal Transport of PQC Components: Motor proteins transport chaperones, ubiquitin, and proteasome components along axons to nerve terminals. This transport is essential for maintaining distal axonal proteostasis, as localized protein synthesis is limited in mature neurons [Gao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31085026/). Disruption of axonal transport, common in neurodegeneration, leads to distal proteostatic failure and axonal degeneration [Millecamps and Julien (2013)](https://pubmed.ncbi.nlm.nih.gov/23615121/).

Synaptic Protein Quality Control: Synapses are specialized compartments with intense protein turnover required for synaptic plasticity. Local PQC at synapses involves synaptic vesicle-associated chaperones and the specific localization of ubiquitin ligases including the presynaptic protein Bruising (BJP) / March1 [Chen et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21389266/)[@chen2011]. Disruption of synaptic PQC contributes to early synaptic dysfunction in Alzheimer's and Parkinson's diseases.

Neuronal Specialized Degradation Pathways: Neurons utilize specific degradation pathways not predominant in other cell types. The neuronal ERAD system contains specialized components including the ubiquitin ligase Parkin and the substrate adaptor protein CDCrel-1 [Zhang et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/11025725/)[@zhang2000]. Additionally, neuronal autophagy exhibits unique regulation through the mTOR-independent pathway involving AMPK and ULK1 activation [Weerasekara et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24819425/).

Disease Relevance

Alzheimer's Disease

[Alzheimer's disease](/diseases/alzheimers-disease) is characterized by extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated [tau](/proteins/tau). Both pathological hallmarks represent failures of PQC to manage misfolded proteins [Soto and Estrada (2008)](https://pubmed.ncbi.nlm.nih.gov/18682243/)[@soto2008].

Amyloid-Beta and Proteostasis: Aβ peptides are generated from amyloid precursor protein (APP) through sequential proteolysis by β- and γ-secretases. The accumulation of Aβ42 (the 42-amino acid isoform) reflects either increased production or decreased clearance. Cellular PQC systems attempt to clear Aβ through the UPS and autophagy, but these systems become overwhelmed or dysfunctional in Alzheimer's disease [Huang et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27234928/). Impaired autophagy in particular contributes to Aβ accumulation, as autophagy is required for extracellular secretion of Aβ and its clearance within neurons [Nilsson et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23792752/).

Tau and Proteostasis: The tau protein normally binds and stabilizes microtubules, but in Alzheimer's disease it becomes hyperphosphorylated, dissociates from microtubules, and aggregates into neurofibrillary tangles. Cellular PQC attempts to clear pathological tau through multiple pathways including the UPS, where tau is ubiquitinated by the E3 ligase CHIP (C-terminus of Hsp70-interacting protein) [Dickey et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17635948/), and through autophagy, where tau is recognized by selective autophagy receptors [Khatoon et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30766941/). Mutations causing familial Alzheimer's disease in APP and presenilin genes may indirectly impair PQC capacity, contributing to disease progression.

Evidence of PQC Failure in Alzheimer's: Post-mortem brain studies reveal widespread accumulation of ubiquitinated proteins in affected brain regions, indicating UPS dysfunction [Dickson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20431186/)[@dickson2010]. Autophagic vacuoles accumulate in neurons, representing impaired autophagic flux [Nixon et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16257968/)[@nixon2005]. The expression of chaperones including Hsp70 and Hsp90 is altered in Alzheimer's brain, with some studies showing upregulation and others showing impairment in chaperone function [Shiota et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21358854/).

Parkinson's Disease

[Parkinson's disease](/diseases/parkinsons-disease) is defined pathologically by the presence of Lewy bodies, cytoplasmic inclusions rich in [alpha-synuclein](/proteins/alpha-synuclein), and the progressive loss of dopaminergic neurons in the substantia nigra. PQC failure plays a central role in alpha-synuclein pathogenesis [Xilouri and Stefanis (2016)](https://pubmed.ncbi.nlm.nih.gov/26219239/)[@xilouri2016].

Alpha-Synuclein and PQC: Alpha-synuclein is a natively unfolded protein that can aggregate into oligomers and fibrils. Cellular PQC systems target alpha-synuclein at multiple points. The Hsp70/Hsp40 system prevents alpha-synuclein aggregation and promotes disaggregation of existing aggregates [Brocker et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22328724/)[@brocker2012]. The UPS degrades monomeric alpha-synuclein, while macroautophagy and CMA degrade aggregate forms [Webb et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12887693/)[@webb2003]. However, alpha-synuclein aggregation can inhibit these degradation pathways, creating a vicious cycle [Tanik et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23658254/).

Genetic Links Between PQC and Parkinson's: Mutations in genes encoding PQC components directly cause familial Parkinson's disease. Loss-of-function mutations in the E3 ligase parkin (PRKN) cause early-onset autosomal recessive Parkinson's disease [Kitada et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9837565/)[@kitada1998]. Parkin functions in mitophagy—the selective autophagy of damaged mitochondria—and its loss leads to mitochondrial dysfunction and neuronal death. Mutations in PINK1 (PTEN-induced kinase 1), which phosphorylates parkin and ubiquitin, also cause familial Parkinson's [Valente et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14739464/)[@valente2004]. Additionally, mutations in the autophagy receptor optineurin (OPTN) and the deubiquitinase USP30 are linked to Parkinson's risk [Lubbe et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33831475/).

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of upper and lower motor neurons. The majority of cases are sporadic, while approximately 10% are familial, often linked to mutations in genes encoding PQC components [Taylor et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27452355/).

TDP-43 and FUS: The RNA-binding proteins TDP-43 and FUS form cytoplasmic inclusions in virtually all ALS cases (except those with SOD1 mutations). Both proteins are normally nuclear and regulate RNA metabolism. Mutations in TARDBP (encoding TDP-43) and FUS cause familial ALS and promote their aggregation [Lagier-Tourenne and Cleveland (2009)](https://pubmed.ncbi.nlm.nih.gov/19749764/)[@lagiertourenne2009]. Cellular PQC attempts to clear these aggregates through the UPS and autophagy, but both pathways are impaired in ALS [Scotter et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25352340/)[@scotter2014].

C9orf72 Hexanucleotide Repeat Expansion: The most common genetic cause of familial ALS is a hexanucleotide repeat expansion in the C9orf72 gene. This expansion leads to toxic RNA foci and dipeptide repeat proteins that impair both the UPS and autophagy [Zhang et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26337853/)[@zhang2015]. The expanded repeat also sequesters nucleocytoplasmic transport factors, disrupting nuclear pore function and proteostasis [Freibaum and Taylor (2017)](https://pubmed.ncbi.nlm.nih.gov/28327665/).

Huntington's Disease

Huntington's disease is caused by CAG trinucleotide repeat expansion in the HTT gene, encoding a polyglutamine (polyQ) tract in the huntingtin protein. Mutant huntingtin (mHTT) forms aggregates that are toxic to striatal and cortical neurons [Soto and Castilla (2011)](https://pubmed.ncbi.nlm.nih.gov/22002716/).

Polyglutamine Aggregation and PQC: The expanded polyQ tract promotes misfolding and aggregation of mHTT. The Hsp70/Hsp40 chaperone system can suppress polyQ aggregation in cellular and animal models, and this protection requires the co-chaperone Hsp40 (DNAJB family) [Muchowski et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10823829/). The UPS degrades soluble mHTT, but aggregated mHTT is largely cleared by autophagy [Kegel et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10823830/). The autophagy receptor p62/SQSTM1 recognizes ubiquitinated mHTT aggregates and targets them for autophagic degradation [Martinez-Vicente et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20378774/)[@martinezvicente2010].

Therapeutic Implications

Understanding PQC mechanisms in neurodegeneration has opened therapeutic avenues targeting proteostasis. Strategies include enhancing PQC capacity, reducing protein misfolding burden, and directly clearing toxic aggregates [Balch et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18682243/)[@soto2008].

Pharmacological Enhancement of Autophagy: Compounds that induce autophagy, including rapamycin (mTOR inhibitor) and trehalose (mTOR-independent), reduce pathological protein accumulation in cellular and animal models [Sarkar et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17640570/)[@sarkar2007]. However, chronic mTOR inhibition has immunosuppressive and metabolic side effects, driving interest in mTOR-independent autophagy inducers [Fleming et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33649895/).

Chaperone-Based Therapies: Small molecules that enhance chaperone activity, termed pharmacological chaperones, are being developed for neurodegenerative diseases. Geldanamycin and its derivatives (17-DMAG, 17-AAG) inhibit Hsp90 and activate the Hsp70 system, reducing aggregation of disease proteins [Waza et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15893379/)[@waza2005]. However, Hsp90 inhibitors have toxicity concerns, prompting development of safer Hsp90 inhibitors and direct Hsp70 activators [Miyata et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23973624/).

UPS Modulation: Enhancing UPS activity is theoretically appealing but challenging, as the proteasome is already highly active under normal conditions. However, enhancing substrate ubiquitination through E3 ligase activation or reducing deubiquitinase activity could increase clearance of specific disease proteins [Roh et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22778252/). The E3 ligase parkin activators are being developed for Parkinson's disease [Kondapalli et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24012328/).

Gene Therapy Approaches: Viral vector-mediated delivery of chaperone genes or autophagy genes represents another therapeutic strategy. Adeno-associated virus (AAV) delivery of Hsp70 to the brain reduces neurodegeneration in animal models [Toth et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18337716/)[@toth2008]. Similarly, gene therapy approaches to enhance autophagy, including expression of Beclin1 or ATG genes, show promise in preclinical models [Zhang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30694139/).

Future Directions

Despite significant progress, key questions remain in understanding PQC in neurodegeneration. How do neurons prioritize between refolding and degradation pathways for specific substrates? What determines when PQC failure becomes irreversible? Can we develop biomarkers to monitor PQC function in patients?

Emerging technologies including cryo-electron microscopy of disease protein aggregates, single-cell proteomics, and systems biology approaches will help address these questions [Ciryam et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28553950/). The development of induced pluripotent stem cell (iPSC) models from patients with PQC gene mutations allows study of human neurons with disease-relevant genetics [Sullivan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28445462/).

Combinatorial approaches targeting multiple arms of the proteostasis network may prove most effective, as the pathways are interconnected and compensate for each other. The ultimate goal—preventing or reversing neuronal protein aggregate accumulation—requires integrated strategies that enhance the entire PQC network while specifically addressing disease-relevant substrates.

See Also

• [alpha-synuclein](/proteins/alpha-synuclein)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [tau](/proteins/tau)
• [Parkinson's disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References